XRTX

+ Watchlist + Portfolio

XORTX Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.00
52-Week Range: $1.73 – $7.05
Market Cap: $3.67M
P/E (TTM): —
EPS (TTM): -2.58
Dividend Yield: —

Advanced Metrics

Price/Book: 1.35
PEG Ratio: —
Return on Equity: -137.44%
Return on Assets: -53.82%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.86
Debt/Equity: 0.01
Total Debt: $15.06K
Free Cash Flow: $-1.62M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $2.77M

XRTX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.76M	$2.42M	$183.83K	$574.93K
Selling, General & Admin	$2.40M	$2.23M	$2.28M	$1.83M
Operating Expenses	$10.29M	$6.05M	$4.12M	$3.26M
Operating Income	-$10.29M	-$6.05M	-$4.12M	-$3.26M
EBITDA	-$10.23M	-$5.91M	-$4.00M	-$3.14M
Pretax Income	-$7.72M	-$2.16M	-$3.31M	-$2.66M
Net Income	-$7.72M	-$2.16M	-$3.31M	-$2.66M
Diluted EPS	-23.54	-5.45	-5.75	-2.80
Diluted Shares	295982	396346	575702	946926

XRTX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$10.43M	$3.45M	$2.47M	$864.51K
Receivables	$81.75K	$60.71K	$17.64K	$80.17K
Current Assets	$10.90M	$4.07M	$2.68M	$1.26M
Total Assets	$12.37M	$5.47M	$4.09M	$2.68M
Current Liabilities	$1.51M	$825.94K	$757.99K	$599.07K
Total Debt	$77.60K	$11.51K	$38.78K	$37.29K
Total Liabilities	$5.38M	$825.94K	$757.99K	$599.07K
Retained Earnings	-$15.70M	-$17.85M	-$21.17M	-$23.82M
Shareholders' Equity	$7.00M	$4.64M	$3.34M	$2.08M
Working Capital	$9.38M	$3.24M	$1.92M	$662.03K

XRTX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$8.17M	-$6.58M	-$3.68M	-$2.77M
Capital Expenditure	-$45.70K	-$46.36K	-$38.92K	-$55.22K
Free Cash Flow	-$8.21M	-$6.63M	-$3.72M	-$2.82M
Depreciation & Amortisation	$58.15K	$139.69K	$117.27K	$112.11K
Stock-Based Compensation	$487.94K	$120.98K	$122.53K	$25.16K
Investing Cash Flow	-$45.70K	-$46.36K	-$38.92K	-$294.95K
Financing Cash Flow	$3.91M	-$361.04K	$2.78M	$1.43M
Net Change in Cash	-$4.30M	-$6.99M	-$938.06K	-$1.64M

XRTX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$276.31K	$186.75K	$57.01K	$54.86K	$33.11K
Selling, General & Admin	$477.80K	$465.83K	$392.94K	$495.11K	$621.87K
Operating Expenses	$963.46K	$889.95K	$716.20K	$686.42K	$823.30K
Operating Income	-$963.46K	-$889.95K	-$716.20K	-$686.42K	-$823.30K
EBITDA	-$937.47K	-$862.32K	-$686.81K	-$657.30K	-$797.45K
Pretax Income	-$698.67K	-$717.70K	-$649.47K	-$590.46K	-$808.47K
Net Income	-$698.67K	-$717.70K	-$649.47K	-$590.46K	-$808.47K
Diluted EPS	-0.93	-0.95	-0.65	—	-0.58
Diluted Shares	747420	757649	971298	—	1.39M

XRTX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$1.90M	$1.06M	$1.19M	$864.51K	$250.28K
Receivables	$17.25K	$10.86K	$22.09K	$80.17K	$64.63K
Current Assets	$2.10M	$1.26M	$1.36M	$1.26M	$744.42K
Total Assets	$3.50M	$2.74M	$2.81M	$2.68M	$2.14M
Current Liabilities	$757.35K	$711.46K	$837.41K	$599.07K	$860.99K
Total Debt	$15.66K	$80.47K	$59.09K	$37.29K	$15.06K
Total Liabilities	$757.35K	$711.46K	$837.41K	$599.07K	$860.99K
Retained Earnings	-$21.87M	-$22.58M	-$23.23M	-$23.82M	-$24.63M
Shareholders' Equity	$2.74M	$2.03M	$1.97M	$2.08M	$1.28M
Working Capital	$1.35M	$553.07K	$520.07K	$662.03K	-$116.57K

XRTX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$643.73K	-$793.52K	-$629.62K	-$701.86K	-$501.36K
Capital Expenditure	-$3.38K	-$21.82K	-$5.49K	-$24.53K	-$3.79K
Free Cash Flow	-$647.12K	-$815.34K	-$635.10K	-$726.38K	-$505.15K
Depreciation & Amortisation	$25.98K	$27.63K	$29.39K	$29.11K	$25.84K
Stock-Based Compensation	$8.97K	$6.95K	$5.12K	$4.12K	$7.82K
Investing Cash Flow	-$3.38K	-$21.82K	-$5.49K	-$264.26K	-$7.92K
Financing Cash Flow	$67.58K	-$43.44K	$770.88K	$632.53K	-$104.20K
Net Change in Cash	-$579.54K	-$858.79K	$135.78K	-$333.58K	-$613.48K

Market Snapshot

About

XORTX Therapeutics is a pharmaceutical company developing therapies to treat progressive kidney disease. The company focuses on xanthine oxidase inhibitors and other compounds to address acute and chronic kidney conditions. XORTX is advancing its pipeline through clinical trials targeting autosomal dominant polycystic kidney disease and other renal disorders.